What was the OCUL analyst rating change on February 17, 2026?

On February 17, 2026 Citigroup maintained an **Outperform** on Ocular Therapeutix, Inc. This was a maintained rating, not an upgrade or downgrade, per the TheFly summary.

Does the Citigroup note include a new OCUL price target?

The TheFly summary of the Citigroup note did not report a new OCUL price target, so there is no updated numeric target in that release. Investors should use prior targets and fundamentals.

How should investors interpret the maintained OCUL analyst rating?

A maintained Outperform shows continued analyst confidence but no fresh catalyst from Citigroup. Investors should combine this view with company milestones and risk tolerance before acting.

What is Meyka AI’s view on OCUL following the rating?

Meyka AI rates OCUL with a grade of **B+** based on benchmarks, sector metrics, growth, and analyst consensus. This reflects balanced upside potential and typical biotech risk.

Analyst Ratings

Citigroup Maintains Outperform on Ocular Therapeutix (OCUL) Feb 17, 2026

ByHuzaifa Zahoor February 18, 2026February 18, 2026

On February 17, 2026 Citigroup maintained an Outperform on Ocular Therapeutix, Inc. (OCUL), the key OCUL analyst rating update this week. We flag the Citigroup call as a vote of confidence despite the recent selloff noted in TheFly report. This action keeps analyst sentiment constructive for OCUL and informs near-term investor decisions. Meyka AI rates OCUL with a grade of B+.